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Defined keywords 
Cyclin-dependent kinase (CDK) – a serine-threonine kinase that is activated in complex with a cyclin 
protein partner 
Cyclin – a protein that activates a cyclin-dependent kinase enzyme 
Cell-cycle CDK – a CDK that is involved in the regulation of the cell cycle  
p16INK4A – cyclin-dependent kinase inhibitor 2A 
RB – retinoblastoma protein 
vAbstract 
Inhibition of cyclin-dependent kinases is an attractive approach to cancer therapy due to their vital 
role in cell growth and transcription. Pan-CDK inhibitors have shown some clinical benefit, and trials 
are ongoing. Selective CDK4 and CDK6 inhibitors have been licenced for the treatment of hormone 
hormone responsive, RB RB-positive breast cancer in combination with anti-hormonal agents. 
Selective inhibitors of CDKs 5, 7, 8, 9 and 12 have been identified across a range of chemotypes.   
 
Introduction 
The Cyclin-dependent kinases (CDKs) are a family of serine-threonine kinases that require binding of 
a cyclin partner protein to become activated.[1] The first CDKs were identified as controlling factors 
in the cell-cycle, with each CDK becoming fully activated at the appropriate point by varying cellular 
concentrations of their cyclin partners (Table 1). Subsequently, additional CDKs and cyclins have 
been identified that play roles outside the cell cycle. In particular, a group of CDKs and cyclins have 
been found to play an important part in the regulation of transcription. CDK5 plays a role in neuronal 
cells in a post-mitotic context.[2] The disregulation of cell-cycle control in cancer has been studied 
for many years, and consequently the central role played by CDKs has led them to be investigated as 
drug targets.[3] This review focuses on recent developments in the design of selective CDK inhibitors 
and discusses novel approaches to CDK inhibition in cancer. 
Table 1: CDK and cyclins 
Cell-cycle related CDKs 
CDK Cyclin partners 
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Transcription related CDKs 
CDK Cyclin partners 
Cdk7 CycH 
Cdk20 
Cdk8 CycC 
Cdk19 
Cdk11 
Cdk10 
CycL 
CycM 
Cdk9 CycT 
Cdk12 
Cdk13 
CycK 
 
 
CDK/Cyclin biology 
Cell cycle CDKs 
The cell cycle is coordinated by the phased activation of CDK1,2,4 and 6 in complex with their cyclin 
partners (Figure 1). Entry to the cell cycle from G0 for quiescent cells is initiated by CDK4 and CDK6 
in response to mitogenic signalling. The activity of CDK4 and CDK6 is regulated by their association 
with three cyclin D paralogues (Cyclins D1, D2 and D3). A number of proteins inhibit CDK4/6 
activation, notably inhibitor of CDK4 (INK4) proteins (p16INK4A, p15INK4B, p18INK4C and 
p19INK4D), that function by inhibiting the kinase activity, and weakening the association with the 
cyclin.[4] 
Activation of CDK4 and CDK6 results in phosphorylation of the retinoblastoma protein (RB) and 
related proteins (RBL1 RBL2). RB is a widely studied tumour suppressor protein that controls the cell 
cycle by forming multiprotein complexes with transcription factors and co-repressors. In particular, 
RB binds to and represses the activity of the E2F transcription factor, and regulates a set of genes 
involved in cell cycle progression including expression of cyclins A, B1 and E. Phosphorylation of RB 
by CDK4 and CDK6 releases E2F and so starts the cell cycle. E2F mediated transcription of cyclin A 
and cyclin E results in the activation of CDK2 that in turn controls DNA-replication and entry to the S-
phase of the cell cycle. CDK2 is inhibited by binding of the CDK-interacting protein/kinase inhibitory 
proteins (CIP/KIP), e.g. p21CIP1 that acts as a DNA-damage checkpoint and p27KIP1 that regulates 
Cdk1 
Cdk2 
Cdk3 
CycA 
CycB 
CycE 
(CycC ?) 
Cdk4 
Cdk6 
CycD(1-3) 
Cdk5 
Cdk14 
Cdk15 
Cdk16 
Cdk17 
Cdk18 
Cdk5R1 
Cdk5R2 
CycD 
CycY 
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mitotic signalling. CDK1 with cyclin A or cyclin B govern entry and progression through the M-phase 
of the cell cycle. CDK1 in complex with cyclin B is solely responsible for the initiation of mitosis, as 
demonstrated by mouse knockout experiments.[5] CDK1 is regulated by checkpoint signalling 
kinases such as CHK1 and WEE1 that phosphorylate and inactivate CDK1.[6] 
 
Figure 1: Cell cycle control by CDKs showing activation () and repression () of key checkpoints by 
phosphorylation (P).. 
 
Non-cell cycle CDKs 
A group of CDKs operate independently of the cell cycle and are largely related to transcriptional 
regulation.[7] CDK7 and CDK9 both phosphorylate RNA-polymerase II, CDK7 is involved in the start 
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of transcription, whereas CDK9 activity is associated with promoting elongation  (Figure 2). CDK8 
acts as a negative regulator of the general transcription initiation factor IIH (TFIIH) targeting the 
CDK7/cyclin H subunits by phosphorylating cyclin H.[8][8] CDK11 acts on the splicing of mRNA. 
 
Figure 2: Transcriptional control by non-cell cycle CDKs showing activation () and repression () of 
key events.. 
The roles of CDK3 and CDK5 are less well understood. CDK3 appears to have a cell cycle role, but the 
presence of endogenous CDK3 inactivating mutationsexpression of inactive mutants in some mice 
suggest that its role is not essential and may be compensated by other CDK/cyclin complexes.[9] 
CDK5 plays a role in the development and functioning of neurons as it is regulated by binding to 
neuron-specific proteins such as p35, and and p25.[10] It is one of the kinases involved in the 
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phosphorylation of neurofibrillary tangles that are associated with neurodegenerative diseases such 
as Alzheimer’s. Small-molecule CDK5 inhibitors are under investigation for this indication.[11–13] 
CDK5 many also have a cell-cycle role similar to CDK4 and CDK2 in some tissue types.[14,15]  
CDKs and cancer 
Disregulation of the control of CDK4 and CDK6 over RB phosphorylation is commonly observed in 
cancer. The tumour suppressor protein p16INK4A acts as inhibitor of CDK4 and CHK6CDK6. Its 
expression is promoted by oncogenic signalling and so ultimately stops uncontrolled 
proliferation.[16] Cancer cells typically avoid this blockade in two ways. Loss of p16INK4A is observed 
commonly in gliomas and releases CDK4 and CDK6 activity allowing cell cycle entry and progression. 
Loss of RB, as seen in small cell lung cancer, deregulates cell cycle signalling and renders cells 
insensitive to p16INK4A overexpression.  Alternatively, CDK4 and CDK6 may be directly activated by 
oncogenic overexpression, polymorphism, abherent splicing, gene translocation, or amplification of 
cyclinD1, which is commonly seen in breast cancer.[17] In addition, amplification or overexpression 
of CDK4 has been reported in specific cancers.[18,19] 
CDK2 phosphorylates a wider range of proteins than CDK4 and CDK6, and its activity is regulated by 
the availability if of its activating E- and A-type cyclins. Amplification of cyclin E1 and E2 has been 
shown to be oncogenic or associated with resistance to therapy in some cancers.[20,21] 
The non-cell cycle CDKs have been proposed as therapeutic targets. In particular, CDK5 appears to 
drive cell cycle progression in medullary thyroid cancer.[26] A number of articles link CDK5 to 
tumour cell motility, migration and invasive potential, often linked with prognosis.[22–25] CDK5 
appears to drive cell cycle progression in medullary thyroid cancer.[26] Recently, CDK5 in tumours 
has been implicated in vasculogenic mimicry by activation of the FAK/AKT pathway, and may be 
associated with poor response to antiangiogenic therapies.[10] [22–25] CDK5 appears to drive cell 
cycle progression in medullary thyroid cancer. Recently, CDK5 in tumours has been implicated in 
vasculogenic mimicry by activation of the FAK/AKT pathway, and may be associated with poor 
response to antiangiogenic therapies.  
CDK7 has been identified as a key transcriptional regulator for an ‘Achilles cluster’ of genes in triple-
negative breast cancer. CDK7 inhibition with kinase inhibitors or CDK7 CRISPR/Cas9 knockdown 
induced apoptosis in triple-negative breast cancer cells.[27]  
CDK8 and its paralogue CDK19 have been found to be upregulated in breast cancer and linked to 
poor prognosis.[28] CDK8 and CDK19 have been identified as negative regulators of super-enhancers 
of the Mediator complex.[28] CDK8 and CDK19 have been identified as negative regulators of super-
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enhancers of the Mediator complex.￼[28]￼ CDK8 and CDK19 have been identified as negative 
regulators of super-enhancers of the Mediator complex.￼[29]￼ Inhibition of CDK8 results in 
upregulation of super-enhancer associated genes in sensitive  (AML) but not in others. Suppression 
of CDK8 in colorec cells with high levels of CDK8 and -catenin hyperactivity inhibits proliferation 
and offers another therapeutic indication for inhibitors. 
CDK9 is identified as an oncogene in a number of solid and haematological cancers. It is involved in  
multiple cellular processes including DNA-repair, transcription and mRNA processing. It is linked 
strongly to cancer as it is involved in the transcription of the MYC oncogene via BRD4-dependent 
recruitment of p-TEFb, and is associated with increased cell survival via Mcl-1 activity.[31]  
CDK11 (previously known as PITSLRE) exists as two isoforms that play different roles. CDK11p58 is 
associated with cell cycle arrest and apoptosis and is a negative regulator of oncogenesis,[32,33] 
whereas CDK11p110 is associated with transcription and is critical for osteosarcoma and liposarcoma 
cell growth.[34,35] CDK11p110 is highly expressed in breast cancer correlating with poor prognosis, 
and knockdown with siRNA inhibits breast cancer cell growth, suppresses invasion, and induces 
apoptosis.[36] Similarly, CDK11 is overexpressed in ovarian cancer and siRNA knockdown inhibits 
growth, induces apoptosis, and sensitises to paclitaxel.[37] 
CDK12 is associated with transcriptional regulation, splicing, embryonal development, and DNA-
damage response via the homologous repair pathway. CDK12 overexpression has been observed in 
breast cancer.[38] A synthetic lethality screen identified CDK12 as conferring sensitivity to PARP1/2 
inhibitor olaparib.[37] Understanding of CDK12 function is not as extensive as for other kinases. 
CDK13 regulates genes required for growth signalling and shows a different gene expression profile 
after knockdown compared with CDK12.[37] CDK14 is upregulated in ovarian cancer and CDK14 
inhibition reduced proliferation, migration and invasion in ovarian cells associated with inhibition of 
the Wnt singalling pathway.[37] 
CDK Inhibitors 
Multiple Pan-CDK inhibitors 
Flavopiridol (alvociclib) (Figure 3: 1) is semi-synthetic flavone that acts an ATP-competitive pan-
kinase inhibitor that shows modest potency and selectivity for CDK1, CDK2, CDK4, CDK6, CDK7, and 
CDK9. Cells treated with 1 show a delay in S phase, consistent with inhibition of CDK2,  followed by a 
block in the cell cycle at G2, which may be caused by inhibition of CDK1 and CDK7.[39,40][39] 
Flavopiridol has been investigated in multiple clinical trials, as a single agent and in combinations, 
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but with low levels of activity and high toxicity seen. Despite these setbacks clinical efficacy was 
demonstrated in haematological cancers, and it received orphan drug status for chronic lymphocytic 
leukemia.[41] 
Roscovitine (seliciclib) (Figure 3: 2), a synthetic purine, is a pan-CDK inhibitor with sub-micromolar 
potency against CDKs 1,2,5,7, and 9 and reasonable selectivity against other kinases. However, a 
Phase II trial in advanced non-small cell lung cancer failed to demonstrate clinical activity.[41]  
Table 2: Pan-CDK inhibitors with IC50s vs CDKs (nd = not determined)  
 
Figure 3: First generation pan-CDK inhibitors. 
Efforts to improve potency and selectivity in CDK inhibitors have resulted in compounds with 
significantly improved potency e.g. dinaciclib (Table 2, 3Figure 4: SCH727965). Dinaciclib 3  displays 
single digit nanomolar potency for CDKs 1, 2, 5 and 7 and selectivity against CDKs 4 ,6, and 7.[42] The 
potency translated into improved cellular inhibition of RB phosphorylation, and activity in preclinical 
models.[43] Phase II studies in solid tumours have not been successful,[44] however, activity in CLL 
has been observed and a Phase III study showed promising results.[45–47] Other pan CDK inhibitors 
(Chart #) Figure 4) that have been investigated in the clinic include: the flavone P276-00 – Phase I/II 
trials in solid and haematological malignancies,[48] roniciclib (BAY 1000394) – Phase I/II trials in solid 
and haematological malignancies,[49] AT7519 –- Phase 1/2I/II study in combination with Hsp90 
inhibitor AT13387 ongoing,[50–53] R547 –- Phase I solid tumours ongoing,[54] SNS-032 – - Phase I 
advanced B-cell malignancies,[55–57] CYC065 – Phase I solid tumours and lymphomas ongoing,[58] 
AZD5438 and AG-024322 – – both tested in Phase I and discontinued, [59,60] milciclib (PHA-848125) 
–  Phase I/II studies in hepatocellular and thymic carcinomas ongoing[59,60] (Figure 3) milciclib 
–  Phase I/II studies in hepatocellular and thymic carcinomas ongoing.  
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Figure 3 4 – Clinically investigated pan-CDK inhibitors, BAY 1000394,[49] AT7519,[50–53], R547,[54] 
SNS-032,[55–57] AZD5438,[59] CYC065,[58] AG-024322,.[60] PHA-848125.[61,62][49] AT7519,, 
R547, SNS-032, AZD5438, CYC065, AG-024322, PHA-848125.[49] AT7519,, R547, SNS-032, AZD5438, 
CYC065, AG-024322, PHA-848125.[49] AT7519,, R547, SNS-032, AZD5438, CYC065, AG-024322, PHA-
848125. 
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 Transcriptional CDK Inhibitors 
design and SAR studies (Figure 45: CDK9 IC50 = 11 nM, CDK8 IC50 = 16 nM, and CDK7 IC50 = 246 
nM).[63] LY2857785 inhibited proliferation and induced apoptosis in a number of cancer cell lines 
and Western blot analysis showed a decrease in antiapoptotic proteins in haematologic cancer cell 
lines, however, toxicity to key organs such as bone marrow was observed in animal toxicity 
studies.[63] 
 
Figure 45: Transcriptional pan-CDK inhibitor 
Selective inhibitors 
CDK4 and CDK6 inhibitors 
CDK4 and CDK6 play a vital role in cells entry into the S-phase of the cell cycle. The discovery of 
multiple modes of their disregulation associated with cancer, identified these kinases as attractive 
targets for inhibition.[64][64]  
Palbociclib (Figure 56: PD-0332991), a selective inhibitor of CDK4/6, was developed from a series of 
pyrido-[2,3-d]-pyrimidin-7-ones. The inhibitor demonstrated activity in tumour cell lines driven by 
cyclin D1-CDK4 or cyclinD2/D3 and CDK6, and showed in vivo activity in tumour models lacking 
CDKN2A but not in models lacking functional RB.[65,66] Palboicilib entered Phase I clinical studies in 
RB positive, advanced tumours. Continuous dosing was associated with toxicity (neutropenia, 
thrombocytopenia), and so a 3 weeks on, 1 week off schedule was adopted.[64,67][64] Palbociclib 
shows clinical activity in a number of tumour types, including mantle cell lymphoma, liposarcoma 
and breast cancer.  
CDKs 4 and 6, and cyclinD are direct transcriptional targets of activated estrogen receptor signalling.  
In estrogen receptor +ve/HER2 -ve breast cancer, treatment in combination with combination with 
tamoxifen showed a synergistic effect. De novo or acquired resistance to ER signalling leads to 
deregulation of CDK4/cyclinD and so G1 checkpoint control.[67] The combination of hormone 
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deprivation therapy with aromatase inhibitors (anastrozole, letrozole) or a selective estrogen 
receptor degrader (fulvestrant) with palbociclib in this setting has been investigated in Phase II/III 
clinical trials and demonstrated significant clinical benefit.[68]  Palbociclib has now been approved in 
the US in this setting in combination with either letrozole or fulvestrant. 
The pyrrolo[2,3-d]pyrimidine-6-carboxamide ribociclib (Figure 56: LEE011) is a selective CDK4/6 
inhibitor that has shown preclinical activity in estrogen receptor +ve/HER2 -ve breast cancer in 
combination with letrozole and phosphatidylinositol 3-kinase inhibitors.[69] A Phase I study in RB 
+ve solid tumours and lymphomas demonstrated safety and preliminary efficacy.[70] A Phase III 
study of ribocilib showed clinical utility and so the drug was approved as a first-line treatment for 
HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor.[71]  
The benzoimidazole abemaciclib (Figure 56: LY-2835219) was developed from a screening hit as a 
potent CDK4/cyclinD1 and CDK6/cyclinD1 inhibitor (KiATP = 0.6 and 2.4 nM, respectively) with good 
selectivity against other kinases.[72]  In RB +ve cells in culture and xenografts, abemaciclib inhibited 
RB phosphorylation and induced cell cycle arrest in G1. Abemaciclib showed pharmacodymamic 
activity and clinical efficacy in a Phase I trial in advanced tumours. Abemaciclib in combination with 
fulvestrant has been approved by the FDA following a successful Phase III trial.[73]  
 
    
   
Figure 56: Selective CDK4/6 inhibitors. 
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CDK5 binds a number of pan-CDK inhibitors including roscovitine (2) in its ATP-binding site.[76] 
Selective CDK5 inhibitors have been identified through high-throughput screening for inhibition of 
Tau phosphorylation A series of selective, non-competitive CDK5 inhibitors were identified by virtual 
screening for binding to the CDK5/p25 X-ray crystal structure. Compounds 4, 5 and 6  (Figure 7) 
inhibited CDK5 activity with IC50s of 0.2, 2 and 17 M, respectively, compound 5 showed non-
competitive inhibition. Virtual screening was used to identify ligands for CDK2 from a 2.84 million 
compound library, were pre-screened using a pharmacophore model and hits were then docked into 
four CDK5/p25 crystal structures. Compounds identified were assayed for CDK2 and CDK5 inhibitory 
activity and CDK5 selective chemotypes progressed to SAR studies that giving thienoquinolone 
derivative 7 (CDK5 IC50 = 3.8 M).[77]  
 
Figure 7: Competitive and non-competitive inhibitors CDK5 inhibitors. 
Selective CDK7 inhibitors 
The first example of a potent and selective CDK7 inhibitor, pyrazole[1,5-α]pyrimidine-derived BS-
181, was designed via computer modelling of the CDK7 ATP-binding pocket and inhibited CDK7 
activity with an IC50 value of 21 nM (Figure 68). Improved potency was displayed over roscovitine, 
which inhibited CDK7 with an IC50 value of 510 nM in the same luciferase assay. BS-181 exhibits 
selectivity over other CDKs, promotes cell cycle arrest, and inhibits cancer cell growth in vitro and 
tumour growth in vivo.[78] Compounds bearing a thieno[3,2-d]pyrimidin-4(3H)-one scaffold have 
been identified as selective CDK7 inhibitors using a pharmacophore model. Compound 1 8 inhibited 
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CDK7 with an IC50 value of 0.70 nM with time-dependent kinetics and a slow off-rate (Figure 
68).[79,80] 
THZ1 was identified in 2014 as a covalent CDK7 inhibitor by cell-based screening of ATP-site-directed 
kinase inhibitors (Figure 68). THZ1 bears an acrylamide moiety which covalently binds to Cys312, a 
residue outside the canonical kinase domain, thus driving potent and selective CDK7 inhibition via a 
novel combined ATP-site and allosteric covalent binding approach.[81] Phosphorylation of RNAPII at 
both the C-terminal domain and the CDK-activating kinase domain is inhibited by THZ1. 
Furthermore, broad-based anti-proliferative activity was observed in 53% of over 1000 cancer cell-
lines screened. Decreased cellular proliferation and increased apoptotic index were observed when a 
T cell acute lymphoblastic leukaemia (T-ALL) cell line was treated with THZ1 and potent efficacy was 
also exhibited in a bioluminescent xenografted mouse model which used human T-ALL cell-line 
KOPTK1, dosed twice daily at 10 mg/kg.[81] CDK7 was validated as a therapeutic target in high-grade 
glioma (HGG) this year using THZ1 as a model inhibitor. THZ1 killed HGG cells via a sequence of 
cellular perturbations which caused both DNA and mitochondrial damage, translation loss and 
spliceosome malfunction.[82] The 3-benzamide analogue THZ2 shows improved in vivo 
pharmacokinetics and showed in vivo activity in triple-negative breast cancer xenografts (MDA-MB-
231). THZ1 showed activity in triple-negative breast cancer patient derived xenografts.[27] Further 
clinical advances are expected soon.  
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Figure 68: Selective CDK7 inhibitors 
Selective CDK8 inhibitors  
Although selective CDK8 inhibitors have been identified, to date they have not reached clinical 
development. The marine sponge alkaloid cortistatin A was described as a selective, high affinity 
CDK8 and CDK19 ATP-competitive binder, with Kd values of 17 nM and 10 nM, respectively (Figure 
79). Antiproliferative activity against human umbilical vein endothelial cells was also observed and 
the compounds appeared attractive as drug discovery leads. Cortistatin A was shown to suppress 
proliferation of several leukaemia cell lines.[29,83,84][72,73] 
Type I inhibitor CCT251545 was discovered following optimisation of an in vitro inhibitor of WNT 
signalling, identified in a high-throughput cell-based reporter assay (Figure 79).[85] CCT251545 is a 
successful example of hypothesis-driven medicinal chemistry optimisation without prior knowledge 
of the biological target, displaying in vitro inhibition of WNT signalling with an IC50 value of 5 nM and 
evidence for tumour growth inhibition following oral dosing in a solid human tumour xenograft 
model.[85] CDK8 and CDK19, two components of the Mediator complex which links RNAPII and 
transcriptional regulators, were later identified as the molecular targets of CCT251545 by cellular 
target profiling. Direct binding was confirmed by surface plasmon resonance (SPR) experiments and 
X-ray co-crystallography of CCT251545 with the CDK8/cyclin C complex.[86] Optimisation to improve 
metabolic stability gave rise to CCT251921 that showed potent inhibition of WNT pathway activity in 
various cancer cell lines.   
A scaffold-hopping approach from CCT251545 to 2 9 was utilised, substituting the 3,4,5-
trisubstituted pyridine series for a 4,6-disubstituted isoquinoline series (Figure 79).[87] Compound 2 
9 inhibited CDK8 with an IC50 value of 5.1 nM in a Lanthascreen TR-FRET assay. Both CCT251921 and 
2 9 suppressed in vivo tumour growth in an APC-mutant SW620 human colorectal carcinoma 
xenograft model.[87]  The same authors identified compounds with a benzylindazole scaffold, 
previously been identified as exhibiting HSP90 inhibition, in a CDK8 high-throughput screen. Lead 
compound 310, inhibited CDK8 with an IC50 value of 10 nM and also inhibited the WNT signalling 
pathway (Figure 7).[88] MSC2530818 was also identified by modifying the imidazo-thiadiazole hit 
identified in the high-throughput screen via scaffold hopping from the original hinge-binding 
motif.[89] In vivo investigation using both 3 10 and MSC2530818 showed reduction in tumour 
phosphorylation of STAT1 Ser727, a biomarker of CDK8 inhibition in an APC-mutant SW620 human 
colorectal carcinoma xenograft model.[88,89] It was noted that the in vitro potency of Type II CDK8 
inhibitors did not translate to cell-based activity, such as with the well-known pan-kinase inhibitor 
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sorafenib.[86] Structure-kinetic relationship studies have been performed using a series of 
arylpyrazole CDK8 inhibitors, which bind in the kinase deep pocket with diverse functional groups 
extending towards the hinge region, and have a similar elongated residence time to 
Sorafenibsorafenib. The flip of the DMG motif resulting from this binding had little influence on the 
binding kinetics in these examples. Hydrogen bonding at the hinge region and hydrophobic 
interactions with the kinase front pocket, however, contributed to the residence time.[90] The 
residence time of a protein-ligand complex is critical when evaluating in vivo biological effects, and 
as such, novel metadynamic stimulations have been developed using the arylpyrazole series.[91] It is 
hoped that the approach can be utilised in future CDK8 drug discovery projects. 
Virtual screening has been utilised this year to identify new compounds with similar scaffolds to 
known Type I and Type II CDK8 inhibitors and also novel and diverse scaffolds.[92] Two 
complementary cascades were used providing 127 hits, of which 33 compounds were potent 
CDK8/CycC inhibitors by enzyme testing and 16 compounds exhibited antiproliferative effects in 
colon cancer cell lines. Three representative scaffolds reduced STAT1 Ser727 phosphorylation in 
HCT116 cells and could hence also be utilised in CDK8 drug discovery projects (Figure 79, 411-
613).[92]  
A novel series of benzoisothiazole CDK8/19 dual inhibitors was identified following structure-based 
drug design using docking studies. Various tricyclic scaffolds with a carboxamide substituent were 
designed to interact with the backbone Ala100 at the CDK8 kinase hinge region.[93] Optimised 
compound 7 14 exhibited high selectivity for CDK8/19 with in vivo vitro IC50 values of 0.46 nM and 
0.99 nM for CDK8 and CDK19, respectively (Figure 79). Selectivity was attributed to the interaction of 
the compound 7 pyridyl group with Met174 of the CDK8 DMG loop. Suppression of phosphorylated 
STAT1 was observed using compound 7 14 in vitro and tumour growth was reduced in RPMI8226 
human hematopoietic and lymphoid xenograft model in mouse.[93] 
Other selective CDK8 inhibitors include thieno[2,3-c]pyridine benzothiophene tool compounds 
(Figure 79, 815) which reduced phosphorylation of STAT1 at Ser727 but did not exhibit 
antiproliferative activity in HCT116 colon cancer cell lines, despite inhibiting CDK8 with an IC50 value 
of 1.5 nM in a LanthaScreen TR-FRET assay.[94] A series of Type II CDK8 inhibitors (Figure 79, 916)  
was also identified by the same group using Sorafenib as a starting point. Whilst a high binding 
affinity in the LanthaScreen TR-FRET assay, with an IC50 value of 17.4 nM, was observed, the 
phosphorylation of STAT1 was not significantly suppressed.[95] This inactivity confirmed the findings 
of Dale et al that Type II inhibitors of CDK8 do not exhibit potent cell-based activity.[86] 
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A series of quinazoline compounds, known as the SNX2 class, in 2012, were shown to inhibit 
damage-induced transcription downstream of p21. Knockout of p21 decreases transcriptional 
activation of some tumour-promoting genes in drug-damaged cells as p21 binds to CDK8, stimulating 
its kinase activity. [96] Senexin A (Figure 79, 1017) bound binds to CDK8 and CDK19 and that p21 
binds to CDK8, stimulating its kinase activity. [83] Compound 10 17 inhibited CDK8 with an IC50 value 
of 280 nM and furthermore, inhibited cytokine production by damaged cells and various paracrine 
activities of chemotherapy-damaged cells in vitro and in vivo. Optimisation of the SNX2 class led to 
Senexin B (Figure 79, 1118) intended for the treatment of breast and prostate cancers.[97] 
Compound 11 18 inhibited CDK8 activity in vitro with and IC50 value range of 24 to 50 nM, depending 
on the assay.[98] Further studies have demonstrated that inhibition of CDK8/19 with Senexin A or 
Senexin B is comparable to shRNA and CRISPR/CAS9 knockout in suppressing oestrogen-induced 
transcription in ER-positive breast cancer cells. In vivo treatment with 11 18 also suppressed tumour 
growth in ER-positive breast cancer xenografts, suggesting CDK8 inhibitors could be utilised for ER-
positive breast cancer therapy.[97] Company information states that their lead CDK8/19 inhibitor is 
undergoing preclinical development, in preparation towards clinical trials in breast and prostate 
cancer.[99][96] Senexin A (Figure 9, 17) binds to CDK8 and CDK19.  Compound 17 inhibited CDK8 
with an IC50 value of 280 nM and furthermore, inhibited cytokine production by damaged cells and 
various paracrine activities of chemotherapy-damaged cells in vitro and in vivo. Optimisation of the 
SNX2 class led to Senexin B (Figure 9, 18) intended for the treatment of breast and prostate cancers. 
Compound 18 inhibited CDK8 activity in vitro with and IC50 value range of 24 to 50 nM, depending on 
the assay. Further studies have demonstrated that inhibition of CDK8/19 with Senexin A or Senexin B 
is comparable to shRNA and CRISPR/CAS9 knockout in suppressing estrogen-induced transcription in 
ER-positive breast cancer cells. In vivo treatment with 18 also suppressed tumour growth in ER-
positive breast cancer xenografts, suggesting CDK8 inhibitors could be utilised for ER-positive breast 
cancer therapy. Company information states that their lead CDK8/19 inhibitor is undergoing 
preclinical development, in preparation towards clinical trials in breast and prostate cancer. 
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Figure 79: Selective CDK8 inhibitors. 
A number of patent applications have been published that describe novel CDK8 inhibitors. Four 
compound series were identified: the phenylpyridine/pyrazine amides (HLR1, 1219),[100] the 
hydroxyethylamino pyridine/pyrazine series (HLR2, 1320),[101] the bi-ring phenylpyridines (HLR3, 
1421),[102] and the pyrrole series (HLR4, 1522)(Figure 810).[103] CDK8 inhibition was observed 
using these compounds in both a CDK8/CycC LANCE TR-FRET kinase assay and an in vitro cell 
proliferation assay on cancer cells, including colorectal cancer HCT116 and gastric cancer AGS cell 
line. Nimbus also reported a tricyclic compound series (Figure 810, 1623), one of which showed 
enzyme inhibitory activity for CDK8 in a mass spectrometry assay. An IC50 value of 22 nM was 
determined against human lung carcinoma A549 live cells.[104] Furthermore, a macrocyclic 
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compound (Figure 810, 1724) was identified which inhibited CDK8 with an IC50 value of 31 nM in a 
LanthaScreen assay.[105] 
A series of trisubstituted benzimidazoles were screened against a panel of kinases and exhibited high 
selectivity for CDK8.[106] Antiproliferative effects against both SW8 and HCT116 cancer cell lines 
were observed with IC50 values of 0.4 and 1.6 µM, respectively, and example 625, numbered as in 
the original publication, showed a reduction in tumour volume in a HCT116 xenograft model 
following a 30 mg/kg dose and 17 days of treatment.[107] According to their Ccompany information 
states that, clinical candidate SEL120-34A has shown good single agent efficacy in numerous animal 
models of various cancer type and is expected to progress into clinical development in 2018. [108] 
SEL120-34A inhibited expression of STAT1 dependent genes in colorectal cancer cell lines and in 
mice bearing HCT116 xenograft tumours.[109] The subset of STAT1 regulated genes were identified 
as interferon-related DNA damage resistance signature (IRDS), providing a combination treatment 
rationale for colorectal cancer,[109] in addition to reported standalone efficacy of CDK8 selective 
inhibitors in vivo. This therapeutic program is the most likely of those selectively targeting CDK8, of 
which information is publicly available, to soon deliver clinical proof of concept.[83] 
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Figure 810: Selective CDK8 inhibitors from patents. 
Selective CDK9 inhibitors 
Several pan-CDK inhibitors exhibit potent CDK9 activity, such as Roscovitine roscovitine and 
Flavopiridolflavopiridol, however, CDK9 inhibitors with good potency and selectivity have only 
recently emerged.[110,111] Arylazopyrazole CAN508 (Figure 911, 1926) selectively inhibited CDK9 
with an IC50 value of 0.35 µM and reduced growth of various cancer cell lines. 19 26 was discovered 
to bind to the CDK9/CycT complex in a hydrophobic pocket adjacent to the C-helix, accessed by 
inducing a conformational change specific to CDK9.[111] 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine 
derivatives, e.g 20 27 (Figure 9), were optimised to inhibit CDK9 with an IC50 value of 7 nM and over 
80-fold selectivity for CDK9 versus CDK2.[110,112] CDK9-mediated RNA polymerase II transcription 
was inhibited and apoptosis triggered in human cancer cell lines and primary CLL cells after 
treatment with lead inhibitor 2027. Differential scanning fluorimetry (DSF) was used to assess the 
binding of the compounds and it was determined that the selective inhibition of CDK9/CycT by 
members of this series results from the flexibility of the CDK9 active site, rather than from specific 
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polar interactions.[113,114] These data have suggested that protein kinases may be more 
susceptible to selective inhibition when in their inactive states.[114] Molecular dynamic simulations 
using 20 27 credited the binding specificity to a conformational change of the G-loop and variations 
in the Van der Waals interactions. The physical properties obtained from the studies could lead to 
the rational design of future selective CDK9 inhibitors.[115] 
Additional early studies towards the development of selective CDK9 inhibitors have identified a 
novel pyrazolo[1,5-a]pyrimidine series.[116] The compounds were designed based on the 
prototypical PI3K𝛼 inhibitor, PIK-75. Compound 21 28 inhibits CDK9 with an IC50 value of 22 nM but 
demonstrates a 100-fold loss of activity compared to PIK-75 in a proliferation assay using leukaemia 
cell line MV4;11.[116] Further studies are required to assess the in vivo pharmacokinetics, 
pharmacodynamics and toxicity of the series.[117] 
Hybrid compound 22 29 was designed by combining the pharmacophores of CDK4/6 inhibitor 
LEE011 and VEGF inhibitor Cabozantinibcabozantinib. Surprisingly, CDK9 was identified as the target 
kinase of 2229, with a CDK9 IC50 value of 12 nM compared to a CDK4 IC50 value of 142 nM. 
Compound 22 29 exhibited potent inhibitory activity in various breast and lung cancer cell lines using 
a CCK8 CDK8 assay and showed good antitumour efficacy in mice using 4T1 xenograft models.[118] 
   
 
Figure 911: Selective CDK9 inhibitors. 
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Selective CDK12 inhibitors 
CDK12 is a transcriptional regulator of homologous recombination deficient cancers and it has 
recently been identified that Dinaciclib dinaciclib reversed acquired resistance to PARP inhibitors in 
BRCA wild-type and mutated models of triple-negative breast cancer, via inhibition of CDK12.[119] 
These results support the combined use of CDK12 and PARP inhibition, however, there is a lack of 
CDK12 inhibitors identified to date.[120] The functions of CDK12 and homologue CDK13 in cancer 
are generally poorly understood, yet it is known that transcription of DNA damage response genes is 
implicated solely with CDK12. Following the discovery of THZ1, Zhang et al designed THZ531 (Figure 
1012, 23) by altering the orientation of the acrylamide moeity, which covalently binds to C1039 of 
CDK12 and to C1017 CDK13, addressing the need for a novel chemical tool.[121] The covalent 
interaction was demonstrated by co-crystallisation of THZ531 with CDK12/CycK.[120] THZ531 
induced a loss of gene expression with concurrent loss of elongated RNA polymerase II, usually 
promoted by phosphorylation of Ser2 by CDK12. THZ531 also induced apoptosis in Jurkat cells.[120] 
These studies highlight the potential of CycK inhibition as a therapeutic strategy for the treatment of 
cancer and it will be useful to next investigate the effect of THZ531 on cancer cell growth.[121] 
 
Figure 1012: Selective CDK12 inhibitor THZ531. 
Alternatives to ATP-competitive inhibitors 
The high degree of similarity in the ATP-binding site between CDKs has prompted alternative 
approaches to their inhibition that offer selectivity by accessing alternative protein surfaces. In the 
case of CDK2 allosteric modulators have been described that bind to and stabilise the inactive 
conformation of the enzyme. The initial observation that the fluorophore ANS (Figure 1113: 2430) 
bound to two sites on CDK2, distinct from the ATP binding site, and induced conformational changes 
in the cyclin binding C-helix,[122] prompted the search for compounds able to bind to the same 
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pockets by virtual screening.[123] Compound 25 31 was identified by virtual screening and 
demonstrated cell growth inhibition.  
 
Figure 1113: Compounds binding to allosteric pocket on CDK2.  
TargettingTargeting the protein-protein interactions within CDK-signalling networks has received 
increasing attention. The homologous proteins CKS1 and 2 play a critical role in cell division. The X-
ray structure of the CDK2-CKS1 reveals that it binds to CDK2 at a different site to the partner 
cyclin.[124] A yeast two-hybrid screen with labelled CDK2 and CKS1 as bait and prey proteins was 
used to screen a small library of natural and synthetic compounds, giving two hit compounds (Figure 
1214, 25 32 and 2633).[125] Both compounds showed activity in an in vitro protein binding assay 
and cellular activity. However, the presence of reactive functionality in both hits suggests that these 
results should be treated with caution.[126]  
 
Figure 1214: CDK2-CKS1 screen hit compounds.  
ConclusionsConclusions 
CDKs play a number of important cellular roles both in the control of progression through the cell 
cycle and in non-cell cycle effects. The first CDK inhibitors developed clinically lacked potency and 
selectivity, and had limited therapeutic effect. Their activity prompted the development of inhibitors 
with improved potency and selectivity profiles.  Optimised pan-CDK inhibitors have been 
investigated extensively, some clinical benefit has been demonstrated, and trials are ongoing. The 
success of these inhibitors will rely on the selection of sensitive patient groups and targetted 
combinations. Selective CDK4 and CDK6 inhibitors have recently been licenced for the treatment of 
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hormone responsive, RB positive breast cancer in combination with anti-hormonal agents. This 
success demonstrates the importance of understanding the underlying tumour biology and 
combination with targetted agents for clinical efficacy. Selective inhibitors of CDKs 5, 7, 8, 9 and 12 
have been identified across a range of chemotypes.  The clinical develoment of these inhibitors is at 
an earlier stage and to date no trials have reported data. Recent approaches to CDK inhibition have 
included targeting allosteric sites or protein-protein interactions. These are aimed at developing 
inhibitors remote from the ATP-binding site, and so offer the prospect of overcoming the selectivity 
problem inherent for ATP-competitive agents. 
Executive Summary 
CDKs and cancer 
 Cell cycle CDKs regulate progression through the cell cycle. CDKs are activated by binding to 
their cyclin partners, and repressed by phosphorylation by regulatory kinases. 
 Non-cell cycle CDKs are independent of the cell cycle, and are activated by binding to their 
cyclin partners. These kinases are mostly associated with controling the machinery of 
transcription.  
 Abherrent control of cell cycle checkpoints is seen in cancer. In particular, CDK4 and CDK6 
phosphorylation of the RB protein, which regulates entry into S-phase, is found disregulated 
in cancer. 
 Non-cell cycle CDKs are associated with cancer in diverse ways that are beginning to be 
understood. 
 CDK inhibitors 
 Cell cycle CDK pan-inhibitors have shown limited clinical efficacy. 
 Selective CDK4/6 inhibition is clinically effective in HR+, RB+ breast cancer in combination 
with anti-hormonal agents. 
 Selective inhibitors of CDKs 5, 7, 8, 9 and 12 have been identified and are in development. 
 The majority of CDK inhibitors discovered to date are ligands for the ATP-binding site, 
alternative approaches to discovering allosteric or non-cometitive inhibitors are underway, and offer 
the prospect of improved selectivity. 
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